Cargando…
A sustainable synthesis of the SARS-CoV-2 M(pro) inhibitor nirmatrelvir, the active ingredient in Paxlovid
Pfizer’s drug for the treatment of patients infected with COVID-19, Paxlovid, contains most notably nirmatrelvir, along with ritonavir. Worldwide demand is projected to be in the hundreds of metric tons per year, to be produced by several generic drug manufacturers. Here we show a 7-step, 3-pot synt...
| Autores principales: | , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Nature Publishing Group UK
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9685088/ https://www.ncbi.nlm.nih.gov/pubmed/36465589 http://dx.doi.org/10.1038/s42004-022-00758-5 |